Aura Biosciences (AURA)
(Delayed Data from NSDQ)
$6.63 USD
+0.02 (0.30%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $6.62 -0.01 (-0.15%) 5:40 PM ET
5-Strong Sell of 5 5
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AURA 6.63 +0.02(0.30%)
Will AURA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AURA
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
AURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for AURA
3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential
Aura Energy Advances Tiris Uranium Project with DFC’s ESIA Publication
Aura Biosciences Holds 2025 Annual Stockholders Meeting
Aura Energy to Release Shares from Escrow, Boosting Market Liquidity
Aura Energy Announces Strategic Development to Boost Market Position